PMID- 33145329
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220830
IS  - 2305-5839 (Print)
IS  - 2305-5847 (Electronic)
IS  - 2305-5839 (Linking)
VI  - 8
IP  - 17
DP  - 2020 Sep
TI  - Does tumor profile in gastric and gastroesophageal (GE) junction cancer justify 
      off-label use of targeted therapy?-a narrative review.
PG  - 1110
LID - 10.21037/atm-20-3510 [doi]
LID - 1110
AB  - Despite significant therapeutic progress, gastric cancer remains among the most 
      deadly forms of cancer encountered in clinical practice, and this remains true 
      even in the context of declining incidence. Outcomes in advanced disease remain 
      poor and therapy is rarely curative in this setting. As our understanding of 
      tumor profile gains sophistication, a growing interest in targeted therapies and 
      moreover the use of tumor profile to inform these therapies has developed in the 
      hopes of altering nearly uniformly poor outcomes. A wide and growing array of 
      molecular targets have been identified in the recent past. Targets of potential 
      clinical interest include human epidermal growth factor receptor-2 (HER2), 
      epidermal growth factor receptor (EGFR), poly(ADP-ribose) polymerase (PARP), 
      mammalian target of rapamycin (mTOR), c-MET, and fibroblast growth factor 
      receptor (FGFR). This advanced molecular understanding has been increasingly used 
      to justify the off-label usage of targeted therapies, though the efficacy of this 
      approach warrants careful consideration. While targeted agents have demonstrated 
      efficacy across a wide range of malignancies, even with molecular profiling data, 
      efficacy is not assured. It will also be demonstrated that even within the same 
      malignancy, what holds true in the metastatic setting does not necessarily apply 
      to the adjuvant or neoadjuvant setting. This review will assess the current 
      evidence for the use of targeted therapies utilizing these biomarkers in the 
      context of gastric and gastroesophageal (GE) junction cancers.
CI  - 2020 Annals of Translational Medicine. All rights reserved.
FAU - Del Prete, Christopher
AU  - Del Prete C
AD  - Division of Hematology Oncology, Department of Internal Medicine, Warren-Alpert 
      School of Medicine at Brown University/Lifespan Health, Providence, RI, USA.
FAU - Muthiah, Arun
AU  - Muthiah A
AD  - Department of Internal Medicine, Warren-Alpert School of Medicine at Brown 
      University/Lifespan Health, Providence, RI, USA.
FAU - Almhanna, Khaldoun
AU  - Almhanna K
AD  - Division of Hematology Oncology, Department of Internal Medicine, Warren-Alpert 
      School of Medicine at Brown University/Lifespan Health, Providence, RI, USA.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - China
TA  - Ann Transl Med
JT  - Annals of translational medicine
JID - 101617978
PMC - PMC7575969
OTO - NOTNLM
OT  - Gastric cancer (GC)
OT  - epidermal growth factor receptor (EGFR)
OT  - human epidermal growth factor receptor-2 (HER2)
OT  - poly(ADP-ribose) polymerase (PARP)
OT  - targeted therapy
OT  - tyrosine kinase inhibitor
OT  - vascular endothelial growth factor (VEGF)
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at http://dx.doi.org/10.21037/atm-20-3510). The series 
      "Gastroesophageal Cancer 2020" was commissioned by the editorial office without 
      any funding or sponsorship. KA served as the unpaid Guest Editor of the series 
      and serves as an unpaid editorial board member of Annals of Translational 
      Medicine from Nov 2019 to Oct 2021. The other authors have no other conflicts of 
      interest to declare.
EDAT- 2020/11/05 06:00
MHDA- 2020/11/05 06:01
PMCR- 2020/09/01
CRDT- 2020/11/04 05:47
PHST- 2020/11/04 05:47 [entrez]
PHST- 2020/11/05 06:00 [pubmed]
PHST- 2020/11/05 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - atm-08-17-1110 [pii]
AID - 10.21037/atm-20-3510 [doi]
PST - ppublish
SO  - Ann Transl Med. 2020 Sep;8(17):1110. doi: 10.21037/atm-20-3510.